The bill mandates coverage for monoclonal antibodies used for the immunization of infants against respiratory syncytial virus (RSV) disease under health benefit plans in Arkansas, effective January 1, 2026. It defines key terms such as "health benefit plan," "healthcare insurer," "infant," and "respiratory syncytial virus disease." The legislation specifies that the coverage for these monoclonal antibodies will not be subject to annual deductibles, copayments, or coinsurance limits, ensuring that it does not diminish or limit other benefits provided under health benefit plans.

Additionally, the bill outlines the responsibilities of the Insurance Commissioner, the Secretary of the Department of Human Services, and the State Board of Finance to promulgate necessary rules for implementation. These rules must be filed with the Secretary of State by January 1, 2026, or as soon as practicable after that date if prior approval is required. The bill aims to enhance healthcare access for infants at risk of RSV disease by ensuring that necessary immunization technologies are covered without additional financial barriers.